What does this video actually claim?
Jess McGirr's TikTok credits tennis champion Serena Williams for her interest in GLP-1 medications, suggesting Williams' public statements influenced her decision. The video has racked up 3.3 million views with just the caption "I blame you Serena Williams."
Williams has been open about her use of semaglutide (Ozempic) for weight management, discussing it in interviews and social media posts. She's described the medication as helpful for managing her weight after pregnancy and retirement from professional tennis.
McGirr's post appears to reference Williams as a catalyst for her own GLP-1 journey. This reflects a broader trend of celebrity endorsements driving public interest in these medications.
Did Serena Williams really promote GLP-1 medications?
Yes, Williams has spoken publicly about using semaglutide. In a 2023 Instagram post, she mentioned using the medication and shared her positive experience. She's been transparent about the challenges of weight management post-pregnancy and after retiring from competitive tennis.
However, Williams has been careful to frame her experience as personal, not medical advice. She's emphasized working with healthcare providers and hasn't made exaggerated claims about the medication's effects.
Her approach differs from some celebrity GLP-1 discussions that minimize potential side effects or oversell benefits. Williams has acknowledged that the medication is "not for everyone" and stressed the importance of medical supervision.
What's the actual evidence on GLP-1 medications?
The clinical data on semaglutide for weight loss is strong. The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% average weight loss at 68 weeks with 2.4mg semaglutide weekly, compared to 2.4% with placebo.
The STEP 2 trial specifically studied people with type 2 diabetes. Participants lost 9.6% of body weight on average with 2.4mg semaglutide versus 3.4% with placebo after 68 weeks.
Common side effects include nausea (44% of participants in STEP 1), diarrhea (30%), and vomiting (24%). Most side effects were mild to moderate and decreased over time. About 7% of people discontinued due to gastrointestinal issues.
Tirzepatide shows even stronger results. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) demonstrated 20.9% average weight loss with the 15mg dose at 72 weeks.
What's missing from celebrity GLP-1 discussions?
Celebrity endorsements often skip the medical complexity of these medications. The starting dose is 0.25mg weekly, gradually increased to minimize side effects. Not everyone reaches the full 2.4mg maintenance dose.
Cost remains a major barrier. Without insurance coverage, semaglutide costs around $1,200 per month. Many insurance plans don't cover GLP-1s for weight loss alone, only for diabetes management.
The medications require ongoing use. In the STEP 1 trial extension, participants who stopped semaglutide regained most of the weight within a year. This isn't a short-term fix.
There are also contraindications. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 shouldn't use these medications. Pancreatitis risk, while rare, is another consideration.
Should celebrity experiences guide your healthcare decisions?
Williams' transparency about her experience is refreshing, but individual results vary significantly. What works for a world-class athlete may not apply to others with different health profiles, lifestyles, or medical histories.
The real issue isn't celebrities sharing their experiences but people making medical decisions based on social media content. A 3.3 million-view TikTok shouldn't replace a conversation with a healthcare provider about whether GLP-1 medications are appropriate.
McGirr's post, while lighthearted, reflects how celebrity influence shapes healthcare choices. That's concerning when these are prescription medications with real side effects and costs. The decision to start a GLP-1 should be based on medical evaluation, not TikTok inspiration.